Hereditary hemochromatosis screening: Effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms

Clinical Genetics

Volumn 71, Issue 1, 2007, Pages 46-58

  Gagne G ^a,b   Reinharz, D ^a,b,c,d,e   Laflamme, N ^b,c,e,f   Adams, P C ^g   Rousseau, Francois ^a,b,c,e  

^a CEDERINDT   (Canada)

^b Université Laval   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d Direction Régionale de Santé Publique de la Capitale Nationale   (Canada)

^e The CanGèneTest Research Consortium on Genetic Laboratory Services   (Canada)

^f INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Cost effectiveness; Health care services; Hemochromatosis; Life expectancy; Penetrance; Population screening; Prevalence; Screening algorithms

Indexed keywords

CYSTEINE; HFE PROTEIN; TRANSFERRIN; TYROSINE;

ARTICLE; CHEMICAL ANALYSIS; COMPUTER PROGRAM; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; GENETIC ALGORITHM; GENETIC ANALYSIS; HEALTH CARE COST; HEMOCHROMATOSIS; HOMOZYGOTE; INTERMETHOD COMPARISON; IRON BINDING CAPACITY; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MASS SCREENING; MUTATION RATE; MUTATIONAL ANALYSIS; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEMOCHROMATOSIS; HUMANS; MUTATION; PREVALENCE;

EID: 33845545966     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2006.00727.x     Document Type: Article

References (57)

1. Witte DL, Crosby WH, Edwards CQ et al. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996: 245: 139-200.
2. Delaveyne R, Greneche S. Évaluation clinique et économique: Intérêt du dépistage de l'hémochromatose génétique en France. Paris: Agence Nationale d'Accréditation et d'Évaluation en Santé(ANAES), 1999: 95.
3. Adams PC, Kertesz AE, McLaren CE et al. Population screening for hemochromatosis: A comparison of unbond iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology 2000: 31: 1160-1164.
4. Moodie SJ, Ang L, Stenner JM et al. Testing for haemochromatosis in a liver clinic population: Relationship between ethnic origin, HFE gene mutations, liver histology and serum iron markers. Eur J Gastroenterol Hepatol 2002: 14: 223-229.
5. Adams PC, Reboussin DM, Barton JC et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005: 352: 1769-1778.
6. Crawford DH, Jazwinska EC, Cullen LM et al. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998: 114: 1003-1008.
7. Girouard J, Giguère Y, Delage R et al. Prevalence of HFE gene C282Y and H63D mutations in a French-Canadian population of neonates and in referred patients. Hum Mol Genet 2002: 11: 185-189.
8. Powell LW, Dixon JL, Hewett DG. Role of early case detection by screening relatives of patients with HFE-associated hereditary haemochromatosis. Best Pract Res Clin Haematol 2005: 18: 221-234.
9. Niederau C, Fisher R, Pürschel A et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996: 110: 1107-1119.
10. Asberg A, Hveem K, Thorstensen K et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001: 36: 1108-1115.
11. Burke W, Thomson E, Khoury MJ et al. Hereditary hemochromatosis gene discovery and its implications for population-based screening. JAMA 1998: 280: 172-178.
12. Cogswell ME, McDonnell SM, Khoury MJ et al. Iron overload, public health, and genetics: Evaluating the evidence for hemochromatosis screening. Ann Intern Med 1998: 129: 971-979.
13. Sham RL, Raubertas RF, Braggins C et al. Asymptomatic hemochromatosis subjects: Genotypic and phenotypic profiles. Blood 2000: 96: 3707-3711.
14. Rossi E, Henderson S, Chin CY et al. Genotyping as a diagnostic aid in genetic haemochromatosis. J Gastroenterol Hepatol 1999: 14: 427-430.
15. Crawford DH, Fletcher LM. Utility of genotyping in diagnosis of genetic haemochromatosis. J Gastroenterol Hepatol 1999: 14: 401-412.
16. Feder JN, Gnirke A, Thomas W et al. A Novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996: 13: 399-408.
17. Nisselle AE, Delatycki MB, Collins V et al. Implementation of HaemScreen, a workplace-based genetic screening program for hemochromatosis. Clin Genet 2004: 65: 358-367.
18. Beutler E. Hemochromatosis: Genetics and pathophysiology. Annu Rev Med 2006: 57: 331-347.
19. Powell LW, Dixon JL, Ramm GA et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006: 166: 294-301.
20. McCullen MA, Crawford DHG, Hickman PE. Screening for hemochromatosis. Clin Chim Acta 2002: 315: 169-186.
21. Beutler E, Felitti VJ, Koziol JA et al. Penetrance of 845G→ A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002: 359: 211-218.
22. Martinez PA, Jeanjean P, Masmejean C et al. Simple and rapid detection of the newly described mutations in the HLA-H gene. Blood 1997: 89: 1835-1836.
23. Bulaj ZJ, Griffen LM, Jorde LB et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996: 335: 1799-1805.
24. Stuhrmann M, Strassburg C, Schmidtke J. Genotype-based screening for hereditary haemochromatosis. I: Technical performance, costs and clinical relevance of a German pilot study. Eur J Hum Genet 2005: 13: 69-78.
25. Rossi E, Bulsara MK, Olynyk JK et al. Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population. Clin Chem 2001: 47: 202-208.
26. Olynyk JK, O'Neill R, Britton RS et al. Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: Diagnostic implications. Gastroenterology 1994: 106: 674-677.
27. Polsky D, Glick HA, Willke R et al. Confidence intervals for cost-effectiveness ratios: A comparison of four methods. Health Econ 1997: 6: 243-252.
28. Lord J, Asante MA. Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis. Health Econ 1999: 8: 323-333.
29. Willis G, Bardsley V, Fellows IW et al. Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: A cross sectional study. BMC Gastroenterol 2005: 5: 17.
30. Lyon E, Frank EL. Hereditary hemochromatosis since discovery of the HFE gene. Clin Chem 2001: 47: 1147-1156.
31. Thorstensen K, Kvitland M, Asberg A et al. 5569G/A polymorphism of the HFE gene: No implications for C282Y genotyping in a hemochromatosis screening study of 65,238 individuals. Genet Test 2000: 4: 147-149.
32. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: A human genome epidemiology (HuGE) review. Am J Epidemiol 2001: 154: 193-206.
33. Stuhrmann M, Hoy L, Nippert I et al. Genotype-based screening for hereditary hemochromatosis: II. Attitudes toward genetic testing and psychosocial impact - a report from a German pilot study. Genet Test 2005: 9: 242-254.
34. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. Ann Intern Med 2000: 132: 261-269.
35. Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 2003: 101: 3347-3350.
36. Adams PC, Reboussin DM, Leiendecker-Foster C et al. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101 168 participants in the hemochromatosis and iron overload screening (HEIRS) study. Clin Chem 2005: 51: 1048-1052.
37. Koziol JA, Felitti VJ, Beutler E. The effect of HFE genotypes on measurements of iron overload. Ann Intern Med 2002: 137: 700-701.
38. Adams PC, Gregor JC, Kertesz AE et al. Screening blood donors for hereditary hemochromatosis: Decision analysis model based on a 30-year database. Gastroenterology 1995: 109: 177-188.
39. Statcan. Profile of Age and Sex, for Canada, Provinces, Territories, Census Divisions and Census Subdivisions, 2001 Census. Statistics Canada, 2002.
40. MSSS. Surveillance de la mortalitéau Québec: 1977-1998. Quebec, Canada: La Direction des communications du Ministère de la Santéet des Services Sociaux (MSSS), 2001.
41. MSSS. Surveillance du cancer au Québec: Nouveaux cas déclarés au fichier des tumeurs et mortalité-année 1993. Quebec, Canada: Ministère de la Santéet des Services sociaux (MSSS), 1996.
42. Alanen KW, Chakrabarti S, Rawlins JJ et al. Prevalence of the C282Y mutation of the hemochromatosis gene in liver transplant recipients and donors. Hepatology 1999: 30: 665-669.
43. Sarasin FP, Majno PE, Llovet JM et al. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 2001: 33: 1073-1079.
44. Bassett ML, Leggett BA, Halliday JW et al. Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers. J Hepatol 1997: 27: 517-524.
45. McDonnell SM, Grindon AJ, Preston BL et al. A survey of phlebotomy among persons with hemochromatosis. Transfusion 1999: 39: 651-656.
46. Barton JC, Preston BL, McDonnell SM et al. Severity of iron overload in hemochromatosis: Effect of volunteer blood donation before diagnosis. Transfusion 2001: 41: 123-129.
47. Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: Decision analysis model comparing genotyping to phenotyping. Am J Gastroent 1999: 94: 1593-1600.
48. RAMQ (Regie de l'assurance-maladie du Quebec). Base de données des services médicaux. Quebec, Canada: Service de la production et de la diffusion de l'information, 2001.
49. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000: 32: 477-481.
50. RAMQ. Manuel des omnipraticiens services de laboratoires en établissement. Quebec, Canada: Régie de l'assurance maladie du Québec (RAMQ), Direction des services àla clientèle professionnelle, 2002.
51. MSSS. Laboratoire de biologie médicale, Mesure de la production Edition 2003-2004. Quebec, Canada: La Direction des communications, Ministère de la Santéet des Services Sociaux (MSSS), 2003.
52. RAMQ. Manuel des médecins spécialistes. Quebec, Canada: Régie de l'assurance maladie du Québec (RAMQ), Direction des services àla clientèle professionnelle, 2001.
53. MSSS. SIFO Système d'Information Financière et Opérationnelle: Méthodologie. Quebec, Canada: Direction de la gestion de l'information, Ministère de la Santéet des Services Sociaux (MSSS), 2002.
54. MSSS. Tarifs interprovinciaux des services externes et procédures coûteuses. Quebec, Canada: Santéet services sociaux, 2004.
55. RAMQ. Manuel des médecins omnipraticiens. Quebec, Canada: Régie de l'assurance maladie du Québec (RAMQ), Direction des services àla clientèle professionnelle, 2002.
56. Merz JF, Kriss AG, Leonard DGB et al. Diagnostic testing fails the test. Nature 2002: 415: 577-579.
57. Drummond MF, O'Brien BJ, Stoddart GL et al. Methods for the economic evaluation of health care programmes, 2nd edn. Paris: Edition Economica, 1997.